Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
Tarsus Pharmaceuticals (TARS) presents a strong "Buy" opportunity with a $72 price target. The company dominates the Demodex blepharitis market with its first-in-class therapy XDEMVY®, demonstrating exceptional commercial execution ($78.3M Q1 2025 revenue, +217% YoY). Supported by a robust balance sheet ($408M cash) and broad payer coverage (>90%), Tarsus leverages its "platform-in-a-product" strategy centered on lotilaner. The synergistic pipeline, particularly TP-04 for Ocular Rosacea, offers significant expansion potential.

Tarsus Pharmaceuticals (NASDAQ: TARS) - Building a First-in-Class Ophthalmic Franchise

2025-07-31Change from report: +80.4%1M: +43.6%3M: +68.6%

Tarsus Pharmaceuticals (TARS) presents a strong "Buy" opportunity with a $72 price target. The company dominates the Demodex blepharitis market with its first-in-class therapy XDEMVY®, demonstrating exceptional commercial execution ($78.3M Q1 2025 revenue, +217% YoY). Supported by a robust balance sheet ($408M cash) and broad payer coverage (>90%), Tarsus leverages its "platform-in-a-product" strategy centered on lotilaner. The synergistic pipeline, particularly TP-04 for Ocular Rosacea, offers significant expansion potential.